Baidu Terminates $3.6 Billion Deal to Buy JOYY's China Live-Streaming Business
By P.R. Venkat
Baidu has called off a $3.6 billion deal to buy JOYY's video-based entertainment live-streaming business in China.
As of the end of December, the closing conditions for the share purchase agreement had yet to be fully satisfied, Baidu said in a filing late Monday.
Some of the closing conditions in the share purchase agreement included obtaining regulatory approvals from governmental authorities.
"The company seeks to discuss with JOYY the next steps following the termination of the share purchase agreement," the Chinese tech company said.
In a separate statement Monday, Nasdaq-listed JOYY said it is seeking legal advice and will consider all options in response to Baidu's notice to terminate the deal.
JOYY announced the deal nearly four years ago, under which Baidu's acquisition would have included the YY mobile app, YY.com website, and PC YY.
The Nasdaq-listed company operates several social products, including Bigo Live, Likee for short-form videos, Hago for multiplayer social networking, and an instant messaging product.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
January 01, 2024 18:52 ET (23:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks